LimmaTech Biologics

About LimmaTech Biologics

LimmaTech Biologics AG is a leader in addressing the global antimicrobial resistance epidemic through advanced vaccine technology and clinical candidate development. The company focuses on creating innovative vaccines to prevent increasingly untreatable microbial infections using its proprietary self-adjuvanting and multi-antigen vaccine platform, aiming to deliver transformative value worldwide.

Products & Services

Proprietary Vaccine Platform:A self-adjuvanting and multi-antigen vaccine platform designed to combat antimicrobial resistant pathogens.

Additional Disease-Specific Vaccine Approaches:Specialized vaccine technologies targeting specific microbial infections.

Specialties

Vaccine Technology Antimicrobial Resistance Clinical Candidate Development Self-Adjuvanting Vaccine Platforms Multi-Antigen Vaccine Platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 3000000 MR: - FA: 3 million FAN: 3000000	D: 2024-02-01 FD: 2024-02-01	4 investors
2	RT: Series A T: - FT: Series A	A: 37000000 MR: - FA: USD 37 million FAN: 37000000	D: 2023-10-09 FD: 2023-10-09	3 investors

Series A Latest

2024-02-01

$3.0M

4 investors (Pro only)

Series A 2023-10-09

$37.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Staph Leavenworth Bakali

Chairperson

LinkedIn (Pro only)

B

Bill Clinton

P

Philippe Dro

Co-Founder & Board Member

C

Camilla Petrycer Hansen

Board Member

F

Franz-Werner Haas

Chief Executive Officer

Z

Zina Affas Besse

Board Member

View 11 more team members with Pro

Unlock Full Team Directory

Recent News